ESTIMATION OF THE TRESHOLD PRICE OF REGORAFENIB IN THE TREATMENT OF UNRESECTABLE AND/OR METASTATIC GASTROINTESTINAL STROMAL TUMORS AFTER FAILURE ON IMATINIB AND SUNITINIB IN SPAIN- COST-UTILITY ANALYSIS

Author(s)

Sanz-Granda Á¹, Hidalgo-Figueruela F¹, Granell M²
¹Weber Economía y Salud, Majadahonda (Madrid), Spain, ²Bayer HealthCare, Sant Joan Despí ( Barcelona ), Spain

Presentation Documents

PCN194-sanz-granda-a-sup-1-sup-hidalgo-figueruela-f-sup-1-sup-strong-u-granell-m-u-sup-2-sup-strong-br-sup-1-sup-weber-economia-y-salud-majadahonda-madrid-spain-sup-2-sup-bayer-healthcare-sant-joan-despi--barcelona--spain

OBJECTIVES: To estimate the threshold price (TP) of regorafenib in Spain to be an efficient option in the treatment of unresectable and/or metastatic gastrointestinal stromal tumors (GIST) that have progressed on imatinib and sunitinib, compared with the best supportive care (BSC)

Conference/Value in Health Info

2015-11, ISPOR Europe 2015, Milan, Italy

Value in Health, Vol. 18, No. 7 (November 2015)

Code

PCN194

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic

Economic Evaluation

Presentation